Answers are grounded in this paper and cite their sources.
Article represents analysis of clinical and biological characteristics and results of treatment of children of first year of life with acute myeloid leukemia. Retrospective analysis included 18 patients under the first year of life received treatment in Republican research center of pediatric oncology, hematology and immunology (Minsk, Belarus Republic). Probability of long-term overall survival was 33 ± 11 %; event-free survival – 28 ± 11 %; cumulative frequency of deaths related to treatment – 66.7 ± 11.7 %; cumulative frequency of relapse – 5.6 ± 5.6 %. Conclusions on age-related correction of cytarabine required.
No takes yet. Share an insight, caveat, or question.
Aleynikova et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: